Description

Ilomedin Concentrate for Infusions 20 mcg/ml. 1ml. №5

Ingredients

Ilomedin concentrate for infusions contains the active ingredient iloprost at a concentration of 20 mcg/ml. Other ingredients may include sodium chloride, hydrochloric acid, and water for injections.

Dosage

Ilomedin concentrate for infusions is administered intravenously. The recommended dosage is determined by the healthcare provider based on the patient’s condition. It is crucial to follow the prescribed dosage and administration instructions carefully.

Indications

Ilomedin concentrate for infusions is indicated for the treatment of peripheral arterial occlusive disease (PAOD) and Raynaud’s phenomenon. It helps improve blood flow and relieve symptoms associated with these conditions.

Contraindications

Ilomedin concentrate for infusions is contraindicated in patients with known hypersensitivity to iloprost or any of the other ingredients in the formulation. It should not be used in patients with severe coronary heart disease, unstable angina pectoris, or acute myocardial infarction.

Directions

Before administration, Ilomedin concentrate for infusions should be diluted according to the instructions provided. The infusion should be given slowly over a specific period as directed by a healthcare professional. Monitoring of the patient during and after the infusion is essential.

Pharmacological Effects

Ilomedin is a synthetic analogue of prostacyclin, a potent vasodilator and inhibitor of platelet aggregation. It acts by dilating blood vessels, improving blood flow, and reducing platelet aggregation, which is beneficial in conditions like PAOD and Raynaud’s phenomenon.

Scientific Evidence and Clinical Trials

Studies have shown the efficacy of iloprost in improving symptoms and quality of life in patients with PAOD and Raynaud’s phenomenon. Research by Fagrell et al. (1999) demonstrated the significant improvement in pain-free walking distance and ulcer healing with iloprost treatment.

Additional Information

It is important to store Ilomedin concentrate for infusions as per the manufacturer’s instructions to maintain its stability and efficacy. Patients should be monitored for any adverse reactions during and after the infusion, and appropriate measures should be taken if any occur.

Overall, Ilomedin concentrate for infusions is a valuable treatment option for patients with PAOD and Raynaud’s phenomenon, offering symptomatic relief and improving blood flow through its pharmacological actions.